396 related articles for article (PubMed ID: 24888274)
21. How many JAK inhibitors in myelofibrosis?
Ferreira BV; Harrison C
Best Pract Res Clin Haematol; 2014 Jun; 27(2):187-95. PubMed ID: 25189729
[TBL] [Abstract][Full Text] [Related]
22. Novel Therapies for Myelofibrosis.
Pettit K; Odenike O
Curr Hematol Malig Rep; 2017 Dec; 12(6):611-624. PubMed ID: 29098608
[TBL] [Abstract][Full Text] [Related]
23. The Role of Megakaryocytes in Myelofibrosis.
Melo-Cardenas J; Migliaccio AR; Crispino JD
Hematol Oncol Clin North Am; 2021 Apr; 35(2):191-203. PubMed ID: 33641863
[TBL] [Abstract][Full Text] [Related]
24. Targeting myeloproliferative neoplasms with JAK inhibitors.
Pardanani A; Tefferi A
Curr Opin Hematol; 2011 Mar; 18(2):105-10. PubMed ID: 21245760
[TBL] [Abstract][Full Text] [Related]
25. Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors.
Randhawa J; Ostojic A; Vrhovac R; Atallah E; Verstovsek S
J Hematol Oncol; 2012 Aug; 5():43. PubMed ID: 22852872
[TBL] [Abstract][Full Text] [Related]
26. Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies.
Tibes R; Mesa RA
J Hematol Oncol; 2014 Mar; 7():18. PubMed ID: 24598114
[TBL] [Abstract][Full Text] [Related]
27. New approaches to tackle cytopenic myelofibrosis.
Reynolds SB; Pettit K
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):235-244. PubMed ID: 36485113
[TBL] [Abstract][Full Text] [Related]
28. Janus kinase inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure?
Harrison C; Verstovsek S; McMullin MF; Mesa R
Br J Haematol; 2012 May; 157(4):426-37. PubMed ID: 22463737
[TBL] [Abstract][Full Text] [Related]
29. Myelofibrosis in 2019: moving beyond JAK2 inhibition.
Schieber M; Crispino JD; Stein B
Blood Cancer J; 2019 Sep; 9(9):74. PubMed ID: 31511492
[TBL] [Abstract][Full Text] [Related]
30. [Recent advances in the treatment of myelofibrosis].
Takenaka K
Rinsho Ketsueki; 2020; 61(9):1195-1204. PubMed ID: 33162516
[TBL] [Abstract][Full Text] [Related]
31. Should we be treating lower risk myelofibrosis patients with a JAK2 inhibitor?
Lancman G; Mascarenhas J
Expert Rev Hematol; 2017 Jan; 10(1):23-28. PubMed ID: 27882812
[TBL] [Abstract][Full Text] [Related]
32. RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis.
Winter PS; Sarosiek KA; Lin KH; Meggendorfer M; Schnittger S; Letai A; Wood KC
Sci Signal; 2014 Dec; 7(357):ra122. PubMed ID: 25538080
[TBL] [Abstract][Full Text] [Related]
33. JAK-mutant myeloproliferative neoplasms.
Levine RL
Curr Top Microbiol Immunol; 2012; 355():119-33. PubMed ID: 21823028
[TBL] [Abstract][Full Text] [Related]
34. Oncogenic Drivers in Myeloproliferative Neoplasms: From JAK2 to Calreticulin Mutations.
Cahu X; Constantinescu SN
Curr Hematol Malig Rep; 2015 Dec; 10(4):335-43. PubMed ID: 26370832
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic approaches in myelofibrosis.
Barosi G; Rosti V; Vannucchi AM
Expert Opin Pharmacother; 2011 Jul; 12(10):1597-611. PubMed ID: 21457082
[TBL] [Abstract][Full Text] [Related]
36. JAK2 inhibitors in the treatment of myeloproliferative neoplasms.
Tibes R; Bogenberger JM; Geyer HL; Mesa RA
Expert Opin Investig Drugs; 2012 Dec; 21(12):1755-74. PubMed ID: 22991927
[TBL] [Abstract][Full Text] [Related]
37. Rationale for combination therapy in myelofibrosis.
Mascarenhas J
Best Pract Res Clin Haematol; 2014 Jun; 27(2):197-208. PubMed ID: 25189730
[TBL] [Abstract][Full Text] [Related]
38. Recent advances in the diagnosis and management of primary myelofibrosis.
Takenaka K; Shimoda K; Akashi K
Korean J Intern Med; 2018 Jul; 33(4):679-690. PubMed ID: 29665657
[TBL] [Abstract][Full Text] [Related]
39. Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia.
Mascarenhas J
Expert Rev Hematol; 2022 Aug; 15(8):671-684. PubMed ID: 35983661
[TBL] [Abstract][Full Text] [Related]
40. JAK2 inhibitors: what's the true therapeutic potential?
Santos FP; Verstovsek S
Blood Rev; 2011 Mar; 25(2):53-63. PubMed ID: 21095048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
